Allergan Company Profile

✉ Email this page to a colleague

ALLERGAN has seventy-three approved drugs.

There are nine US patents protecting ALLERGAN drugs.

There are one hundred and eighty-one patent family members on ALLERGAN drugs in fifty-five countries and one hundred and sixteen supplementary protection certificates in eighteen countries.

International Patents:	181
US Patents:	9
Tradenames:	70
Ingredients:	54
NDAs:	73
Patent Litigation for Allergan:	See patent lawsuits for Allergan
PTAB Cases with Allergan as patent owner:	See PTAB cases with Allergan as patent owner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	8,471,025	⤷ Try a Trial		Y		⤷ Try a Trial
Allergan	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-003	Mar 12, 2015	AB	RX	Yes	No	8,022,228*PED	⤷ Try a Trial			Y	⤷ Try a Trial
Allergan	HMS	medrysone	SUSPENSION;OPHTHALMIC	016624-003	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	BYSTOLIC	nebivolol hydrochloride	TABLET;ORAL	021742-004	Dec 17, 2007	6,545,040	⤷ Try a Trial
Allergan	GELNIQUE 3%	oxybutynin	GEL, METERED;TRANSDERMAL	202513-001	Dec 7, 2011	7,029,694	⤷ Try a Trial
Allergan	PROPINE	dipivefrin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	018239-001	Approved Prior to Jan 1, 1982	3,839,584	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Capsules	60 mg	➤ Subscribe	2009-03-02
➤ Subscribe	Transdermal System Extended-re	3.9 mg/24 hrs	➤ Subscribe	2008-08-19
➤ Subscribe	Ophthalmic Solution	0.30%	➤ Subscribe	2007-07-19
➤ Subscribe	Tablets	2.5 mg, 5 mg, 10 mg, and 20 mg	➤ Subscribe	2011-12-19
➤ Subscribe	Sublingual Tablets	2.5 mg	➤ Subscribe	2017-07-27
➤ Subscribe	Capsules	4 mg and 8 mg	➤ Subscribe	2012-10-09
➤ Subscribe	Ophthalmic Solution	0.05%	➤ Subscribe	2008-10-14
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Sublingual Tablets	5 mg and 10 mg	➤ Subscribe	2013-08-13

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0398460	12/2004	Austria	⤷ Try a Trial	PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
1480644	C01480644/01	Switzerland	⤷ Try a Trial	PRODUCT NAME: AVIBACTAM + CEFTAZIDIM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66890 05.06.2019
1453521	15C0050	France	⤷ Try a Trial	PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.